Alebund Pharma wins US FDA clearance to start AP308 IgA nephropathy trial

• Alebund Pharmaceuticals (Jiangsu) secured FDA clearance for an IND for AP308 in IgA nephropathy.
• Approval enables the start of a first-in-human clinical trial, which the group plans to launch shortly.
• AP308 is an engineered recombinant IgA protease designed to cut pathogenic IgA1 complexes implicated in the disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alebund Pharmaceuticals (Jiangsu) Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260908-12325086), on September 08, 2026, and is solely responsible for the information contained therein.